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(The paper by Hsu et al. (1) in this issue of iJACC
presents the results of a validation study on the use
of cardiac magnetic resonance (CMR) imaging to
map myocardial blood flow (MBF) at the spatial
resolution of the underlying images (“pixel-wise”),
acquired during the first pass of a gadolinium
contrast bolus injection. This work raises 2 inter-
esting questions: do we need pixel-level resolution
for mapping MBF, despite the prevalent use of
simpler and robust methods, which are exemplified
by the bull’s-eye plot, well known from nuclear
See page 154
cardiac imaging? And, what is to be gained by
mapping, not just the relative distribution of blood
flow, but also the absolute MBF in units of milli-
liters/minute/gram of tissue? Though the study by
Hsu et al. (1) did not try to explicitly address these
questions, the longer-term, clinical application, and
significance of the reported technique depends on
how these questions are answered.
For the first question, which pertains to the
spatial resolution of perfusion maps, one can draw
on ample evidence from experimental and clinical
studies that demonstrate the benefits depicting
myocardial perfusion with at least a resolution that
is adequate to resolve blood flow deficits limited to
the subendocardial layer. Given that the in-plane
resolution achieved with most CMR “first-pass”
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to the contents of this paper to disclose.erfusion studies averages currently between 2 to 3
m, a pixel-wise measurement is commensurate
ith the requirements for detecting subendocardial
schemia. But, imaging with higher spatial resolu-
ion also generally entails more noise, and this
qually applies to noise levels in MBF maps that are
enerated from images. Nevertheless, it can be
rgued that the Achilles heel of CMR perfusion
maging is not the random noise, but rather the
rtifacts that can mimic perfusion defects (2). In
his respect, the algorithms that are used to generate
lood flow maps at the pixel level may help reduce
he susceptibility to false-positive results. The algo-
ithms, including the one used in the study by Hsu
t al. (1), represent the myocardial contrast en-
ancement as a linear response to the contrast
nhancement in the blood pool. Transitory, suben-
ocardial dark rim artifacts seen during CMR
rst-pass imaging are therefore effectively sup-
ressed from the blood flow maps. Though this
spect was not investigated in detail in the study by
su et al. (1), such benefits emerged from earlier
tudies of MBF quantification by CMR (3).
This last point already answers part of our second
uestion: what is to be gained from pixel-wise
easurements of absolute MBF, rather than assess-
ng the level, or rate, of contrast enhancement? The
atter only allows an assessment of regional differ-
nces within the same heart. A recent publication
y Patel et al. (4) demonstrated that with multives-
el coronary artery disease, one should look with
MR beyond the visual detection of regional,
ontrast-enhancement deficits, and also quantify
he myocardial perfusion reserve to significantly
mprove the detection of flow limiting coronary
isease. Quantifying MBF during maximal vasodi-
ation, as was performed in the study by Hsu et al.
1), should at least provide equivalent benefits as the
yocardial perfusion reserve quantification, and
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168eliminate the potentially confounding effects of an
abnormal level of MBF at rest (5). Furthermore, for
pixel-wise maps, the operation of calculating a
perfusion reserve ratio is bound to amplify any noise
in the resting perfusion measurements, which is the
denominator in the perfusion reserve ratio. Argu-
ably, 1 merit of the study by Hsu et al. (1) is,
therefore, the effort to quantify absolute blood flow,
rather than a quantity that approximates a perfusion
reserve ratio. A further advantage is that a MBF
map, in comparison to the underlying images,
brings out differences in hyperemic flow more
clearly. To appreciate this point, one should note
that with a peripheral injection of contrast, equal
increments in blood flow result in diminishing
increases of contrast enhancement, as absolute
MBF increases. Or stated differently, an increase of
MBF from 2.5 ml/min/g to 3.0 ml/min/g produces
a considerably smaller difference in peak contrast
enhancement than an equal (0.5 ml/min/g) incre-
mental change from 0.75 to 1.25 ml/min/g. With
the blood flow maps, this “perfusion-myopia” is
removed. A relatively open question is how the
information derived from MBF values should be
interpreted for the clinical diagnosis of myocardial
ischemia and the determination of the extent of
an ischemic zone, as MBF can at best only be a
surrogate marker of ischemia. It is also still unclear
whether or not this novel MBF assessment will
significantly change patient prognosis. This can
only be addressed by trials where MBF quantifica-
tion is included in the outcome measures.
A further concern is the still widely prevalent
need for manual image segmentation to generateperfusion studies. Magn Reson Med
2005;54:1295–9.
3
4
5
6. Wang L, Jerosch-H
DR Jr., Shahar E, Dthe process, as exemplified by the methods de-
scribed by Hsu et al. (1), have shown promise and
are being adopted by at least 1 CMR equipment
vendor for pre-clinical evaluation.
Despite the important benefits of MBF quanti-
fication, one has to take note of the sobering fact
that, irrespective of imaging modality and of the
considerable work invested in imaging-based MBF
quantification, there is still relatively little demand
in the clinical community for such quantitative tools
in CAD diagnosis. The quantification of absolute
MBF may in fact be more compelling for other
etiologies that are characterized by microvascular
coronary dysfunction, or subclinical, diffuse athero-
sclerosis (6), rather than focal ischemia caused by
flow-limiting coronary disease in the epicardial
arteries.
An important merit of the work by Hsu et al. (1)
is to have developed a novel method that addresses
simultaneously and effectively both MBF quantifi-
cation and pixel-wise perfusion mapping. In the
clinical realm, a new prescription to view CMR
perfusion studies may not find immediate reso-
nance, but for a further elucidation of coronary
physiology in various cardiac diseases, any prescrip-
tion that improves our perceptive powers to eluci-
date coronary physiology and disease, and avoids
“perfusion myopia,” will surely be welcomed
quickly.
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